JEITO’S TEAM

Alain is the Founding Partner of Prodensia, a company specialising in outsourcing financial management for investment funds, which was created in 2015.

Previously, Alain was Chief Financial Officer / Secretary General of investment funds for 10 years, after having spent 10 years in Audit in France and abroad.

Alain has been part of Jeito team since the beginning, participating to the firm’s evolution since January 2020 as acting CFO. He brings his experience, his expertise and his resources to support Jeito’s growth, coordinating the financial team’s activities and managing the firm’s structuring projects.

*External provider (Prodensia)

Daniel is a Principal at Jeito Capital, working in the investment team as Portfolio Manager.

Prior to joining Jeito, Daniel worked at J.P. Morgan as an Equity Research Analyst, covering the biotechnology sector across a wide range of therapeutics and modalities. Daniel began his career in the financial markets as an analyst at Piper Jaffray (now Piper Sandler), covering the equity story of American and European biotech and pharmaceutical companies.

Daniel holds a Ph.D. in Molecular Biology from Princeton University and a Bachelor of Science’s degree in Biochemistry from University of California, Los Angeles.

As a Finance manager, Estelle works on the finance monitoring of Jeito funds and portfolio companies, alongside with the investment team.

Before joining Jeito, Estelle was a Financial auditor at EY, where she specialised in the healthcare sector, working with Biopharmas and MedTech companies on internal control implementation and financial reporting process improvement.

Estelle holds a Master of Accounting Control Auditing from the University Paris Dauphine.

As a Project Manager, Manon supports Jeito Capital’s Investor Relations activities and its communication initiatives.

Before joining Jeito, Manon worked in investment banks specialising in Healthcare, where she was involved in M&A and financing transactions for Biotech, MedTech and digital health companies, as well as private clinics. She also has previous experience in management control and internal audit within large groups.

Manon holds a Master’s degree in Management and Corporate Finance from Audencia Business School, Grande Ecole programme.

Benjamin joined Jeito Capital in 2023.

Prior to joining Jeito, Benjamin was Chief Financial Officer of holding companies, investment companies and family offices for more than 15 years, in France and Luxembourg.

Benjamin holds a Master’s degree in Business Administration, specialised in Finance and Strategy from ESCE Paris.

Noemie is an Associate in the investment team at Jeito Capital, following a previous experience as Junior Analyst Intern.

Noémie had previous experiences in the healthcare industry including business development in a start-up company developing AI-driven diagnostics for neurodegenerative disorders.

Noémie holds a master’s in management from ESCP Business school, Grande Ecole Programme. In addition, Noémie was a visiting student at New York University with a core focus in Biology and Biotech Strategy.

Chloé is an Analyst at Jeito Capital.

Before joining Jeito, Chloé had previous experiences in Healthcare investment both in Venture Capital at Auriga Partners and in listed equity as a Healthcare buy-side financial analyst at DNA Finance. At DNA Finance, she also supported early-stage biotech companies in their fundraising efforts.

Chloé also participated to the support of entrepreneurship and innovation in Healthcare through her experiences at Bpifrance and Hello Tomorrow.

Chloé holds an Engineer’s degree from AgroParisTech and a Master’s degree in corporate finance and strategy from Sciences Po Paris.

Hortense is Finance Manager within Jeito Capital’s finance team. She participates in the financial and administrative management of Jeito’s fund, and in the financial monitoring of portfolio companies alongside the investment team.

Prior to joining Jeito, Hortense worked as a Financial auditor at KPMG. She quickly specialised in the Healthtech sector through auditing biopharmaceutical companies, both private and public, and contributing to the drafting of internal studies on key financial topics of the life sciences’ sector as well as market trends.

Hortense holds a Master in Audit and Accounting from Neoma Business School.

Henri is a Legal Counsel at Jeito Capital.

Prior to joining Jeito, Henri worked for more than 5 years at Weil, Gotshal & Manges (Paris) LLP as an attorney in the private equity team, where he advised private equity funds and corporates on LBO, M&A and growth deals.

Henri is a member of the Paris Bar and a graduate from Paris Panthéon-Assas University (Master’s degree in Business Law and Tax) and ESCP Business School (Master in Management – Programme Grande Ecole).

As Compliance Officer, Boris assists Jeito Capital’s Head of Sustainability, Compliance & Risk with compliance and internal control issues, particularly with regard to AMF regulations.

Before joining Jeito Capital, Boris was a compliance and internal control consultant at AGAMA Conseil. He assisted portfolio management companies specializing in private equity.

Boris previously worked at a law firm in Luxembourg (Dentons) in the investment funds department. In particular, he was involved in structuring management companies (AIFMs) and Luxembourg investment vehicles (SCSp).

Boris holds a Master’s 1 in Business Law and Taxation and a Master’s 2 in International Business Law from the Faculty of Law of Nancy (University of Lorraine).

Prior to joining Jeito Capital, Ivana gained healthcare investment experience as a Junior Analyst within the Biofund team at Kurma Partners.

Earlier in her career, she served as a Scientific Advisor to several private biotechnology companies.

Ivana holds a PhD in Neurobiology from the Interdisciplinary Institute for Neuroscience of the University of Bordeaux and has completed additional training in Venture Capital and Entrepreneurship at the University of Oxford.

Prior to joining Jeito, Elana gained Healthcare investment experience working for Neuro.VC, a San Fransico-based Venture Capital fund. Her experience in high-impact academic research contributed to publications in Science, Nature, and Cell and she was awarded an NIH F31 Fellowship.

Elana holds a PhD in Neurobiology from Duke University and a BA in Neuroscience from Boston University.

Prior to joining Jeito, she worked as an Executive Assistant, assisting 5 partners within the sustainability practice at EY France. She started her career in London before joining Cathay Capital in Paris as Executive Assistant to the firm’s Managing Partners.

Before joining Jeito, Olga worked for more than 4 years as Executive Assistant in a Family Office & Communication firm. Before that, she worked for more than 15 years in Events agencies.

Olga holds a PhD in Comparative Literature from the University of Paris XII, along with advanced degrees in Intercultural Literature and Tourism Marketing from French institutions, and a Master’s in Literature from Novosibirsk State University in Russia.

Before joining Jeito, Sarah worked for more than 4 years as Executive Assistant at LionTree, a US Investment Bank based in Paris. Before that, she worked for 5 years at the Fondation Giacometti, participating in the launch of the Institut Giacometti.

Sarah completed the French humanities preparatory classes, Hypokhâgne and Khâgne and also received training in accounting and management.

Samit brings over 25 years of senior leadership and clinical development experience at top-tier international pharmaceutical groups.

Most recently, Samit Hirawat, M.D., served as Chief Medical Officer, Executive Vice President, and Head of Global Drug Development at Bristol Myers Squibb, where he oversaw the worldwide clinical development portfolio and advanced multiple transformative therapies across therapeutic areas and modalities to registration trials and approvals. Prior to that, he spent more than a decade at Novartis Pharmaceuticals in roles of increasing strategic responsibility, leading to his position as Executive Vice President and Head of Oncology Development.

Samit Hirawat, M.D., earned his Bachelor of Medicine and Bachelor of Surgery (MBBS) from Sawai Man Singh Medical College. He completed his Internal Medicine residency and Medical Oncology fellowship at North Shore University Hospital. He has published more than 150 peer-reviewed manuscripts and abstracts across therapeutic areas.

Elaine brings 30 years of leadership experience across top-tier life sciences investment funds, pharma and biopharma companies, spanning business development, commercial operations, market access, and investing.

Prior to Jeito, Elaine served as Deputy Chief Operating Officer at Blackstone Life Sciences (BXLS), based in Cambridge (MA) where she worked on fund operations, Limited Partner engagement, co-investments, and interacted closely with the investment team.

Before that, she was the Chief Business Officer at Kymera Therapeutics (NASDAQ: KYMR) where she was responsible for licensing and pharma partnerships.  She was also CBO of privately held Cygnal Therapeutics, Inc. (now Sonata Pharmaceuticals). She also gained substantial experience at Biogen, where she worked in business development, completing several large global partnerships in oncology, neurology, and immunology.  At Biogen, she also served as Head of Strategy and Operations, Global Market Access where she took part in several drug launches. She began her career after business school in venture capital, investing in clinical stage biotech and med-tech start-ups with MPM Capital and ATV Capital.

Elaine holds a bachelor’s degree in economics from Wellesley College and an MBA from Harvard Business School.

Sarah Shackelton brings over two decades of experience building high calibre senior leadership teams and boards in life sciences, health tech and deep tech – working at the intersection of investment and talent to help innovative, VC-backed companies’ scale.

Prior to Jeito, Sarah was Chief Talent Officer at Oxford Science Enterprises. She partnered with investment and leadership teams to build high-performing boards and senior teams for a broad portfolio of science-based companies. Before that, as Partner, Marketing and Talent at Abingworth, she led the people and talent strategy for a leading transatlantic biotech investor, spanning early and late-stage portfolio companies and network development. Before moving to investment firms, she worked in executive search across the Biopharma, PE/VC and technology practices of global and boutique firms, including Coulter Partners and Spencer Stuart. She began her career as a U.S. Government trade negotiator, working closely with the pharma industry.

Sarah holds a MPA in Economics and Political Science from Princeton University and a bachelor’s degree in international relations from Pomona College. She is a member of Women Innovating Together in Healthcare (W.I.T.H.) and sits on its steering committee.

Magdalena brings 15 years of international biopharma experience across strategy, investing and operating. Her deep scientific expertise, commercial acumen and operational leadership are complemented by a proven track record in investing, company creation and board leadership.

Prior to Jeito, Magdalena was a Partner at Syncona Ltd., where she led the creation, financing, and strategic development of therapeutics companies including OMass Therapeutics, Kesmalea Therapeutics and Mosaic Therapeutics. She served as an investor director on portfolio company boards, and took on operating leadership responsibilities, including as interim CEO of Mosaic Therapeutics.

Before that, Magdalena was an Associate Partner at McKinsey & Company in Palo Alto (USA) and London (UK), where she advised global pharmaceutical and healthcare clients on strategy across the value chain, and led commercial due diligence across therapeutics, medtech, and services.

Magdalena completed a postdoctoral fellowship at Harvard Medical School and Boston Children’s Hospital (USA) after earning a Ph.D. and an M.S. in Bioengineering from Stanford University (USA), and a Bachelor of Science in Engineering (BSE) in Bioengineering from the University of Pennsylvania (USA).

Anastasiya Sybirna, PhD, joins Jeito as a Principal, bringing strong biopharma experience across Biopharma investing and strategy consulting.

Before joining Jeito, Anastasiya was a Senior Associate at Fidelity-backed F-Prime Capital, where she focused on healthcare investments and served as an investment lead. Prior to F-Prime, Anastasiya was an Engagement Manager at McKinsey & Company, specializing in Pharmaceuticals & Medical Products, and previously worked as a Strategy Consultant at Advancy.

Anastasiya holds a PhD in Stem Cell Biology and Medicine from the University of Cambridge, an MSc in Molecular and Cell Biology from École normale supérieure in Paris, and a BSc in Biology from Ivan Franko National University of Lviv in Ukraine.

Ana Leticia brings over 10 years of professional experience in pharmaceutical industry as project leader in drug discovery and translational research.

Ana Leticia joins from Servier, where she has worked for more than 10 years, first as a Postdoctoral Fellow in Oncology and then as a Project Leader, contributing to shaping Servier’s oncology drug discovery strategy. She has led several drug discovery projects from target identification until clinical development, covering small molecules, antibodies and ADCs. She has also established long-term collaborations with big pharma and biotechnology companies, and has been involved in in-licensing and M&A due diligence.

Ana Leticia holds a PhD in cellular and molecular biology from Institut Curie, a Master’s degree in biochemistry from Universidade de São Paulo and a Pharmacist Degree from Universidade Estadual Paulista Julio de Mesquita Filho.